Aktienanalyse zu STERIS plc (STE)STESTERIS plc

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

STERIS plc is a good buy right now due to its current price of $222.66, which is below the analyst price target of $275 from UBS, indicating significant upside potential. Additionally, the company has shown a strong gross margin of 43.89% in the latest quarter, reflecting solid profitability. However, the main risk is the recent decline in free cash flow, which dropped to $279.6 million from $326.5 million year-over-year, highlighting potential cash management challenges.

8 analysts cover STE: 6 rate it Buy, 2 Hold and 0 Sell.